Evidence map›Paper›PMID 36010849›Full record

ArticleCancers2022

HSF1 Stimulates Glutamine Transport by Super-Enhancer-Driven lncRNA LINC00857 in Colorectal Cancer.

Qi Shen, Rui Wang, Xinling Liu, Ping Song, Mingzhu Zheng, Xiaomin Ren, Jingang Ma, Zhong Lu, Jiaqiu Li

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 32 citations in OpenAlex.

  1. Crosstalk BetweenCancers · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Pan-cancer analysis reveals the prognostic and immunomodulatory potential of super-enhancer-induced ANGPT2 and experimental validation in colorectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. HSF1 Activation Mechanisms, Disease Roles, and Small Molecule Therapeutics.International journal of biological sciences · 2025
    Review
  13. The role of super-enhancer-driven lncRNAs in cancer.Computational and structural biotechnology journal · 2025
    Review
  14. Review
  15. Article
  16. Super enhancer lncRNAs: a novel hallmark in cancer.Cell communication and signaling : CCS · 2024
    Review
  17. Article
  18. Review
  19. Metabolic reprogramming directed by super-enhancers in tumors: An emerging landscape.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Qi ShenDepartment of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230002, China.
Rui WangDepartment of Oncology, Clinical Research Center, Affiliated Hospital of Weifang Medical University, Weifang 261031, China.
Xinling LiuDepartment of Oncology, Clinical Research Center, Affiliated Hospital of Weifang Medical University, Weifang 261031, China.
Ping SongDepartment of Gastroenterology, Affiliated Hangzhou First People's Hospital, Medical School of Zhejiang University, Hangzhou 310006, China.
Mingzhu ZhengDepartment of Oncology, Clinical Research Center, Affiliated Hospital of Weifang Medical University, Weifang 261031, China.
Xiaomin RenDepartment of Oncology, Clinical Research Center, Affiliated Hospital of Weifang Medical University, Weifang 261031, China.
Jingang MaDepartment of Oncology, Clinical Research Center, Affiliated Hospital of Weifang Medical University, Weifang 261031, China.
Zhong LuDepartment of Oncology, Clinical Research Center, Affiliated Hospital of Weifang Medical University, Weifang 261031, China.
Jiaqiu LiDepartment of Oncology, Clinical Research Center, Affiliated Hospital of Weifang Medical University, Weifang 261031, China.ORCID 0000-0002-2292-6651
Weifang Medical University · CNHangzhou First People's Hospital · CNUniversity of Science and Technology of China · CN

Funding

National Natural Science Foundation of China 81902404Natural Science Foundation of Anhui Province 1708085QH193Natural Science Foundation of Shandong Province ZR2019BH009Natural Science Foundation of Shandong Province ZR2020QH096Provincial Quality Project of Anhui Colleges and Universities 2020jyxm2314the Project of Shandong Province medical science technology development plan 2017WS403, 2019WS601
6 · The paper itself

Abstract

Super enhancers are critical for the gene transcription responsible for cell fate by interacting with transcription factors. However, the relevance of HSF1 to super enhancers in tumors remains obscure. We profiled H3K27ac enrichment by chromatin immunoprecipitation sequencing. HSF1-mediated lncRNAs were identified by lncRNA microarray. The characteristics of LINC00857 were explored by in vitro and in vivo assays. The mechanism was studied via chromatin immunoprecipitation, RNA immunoprecipitation, and HSF1/ANXA11 knockout mice. We found that super enhancers occupied multiple gene loci in colorectal cancer. We screened out an HSF1-mediated super enhancer, lncRNA-LINC00857, which exerts its characteristics in promoting cell growth via regulating glutamine metabolism. Notably, HSF1 could stimulate the super-enhancer activity of LINC00857 by the enrichment of acetyltransferase P300 to its gene loci, contributing to LINC00857 transcription. In turn, nuclear LINC00857 cooperated with HSF1 to promote ANXA11 transcription, which modulated SLC1A5/ASCT2 protein expression by binding competitively to miR-122-5p. The knockout of ANXA11 attenuated colorectal cancer formation in vivo. Collectively, we shed light on a closely cooperative machinery between HSF1 and super enhancers. HSF1 could stimulate acetyltransferase P300-mediated super-enhancer activity to facilitate LINC00857 expression, contributing to SLC1A5-mediated glutamine transport. Targeting the HSF1/LINC00857/ANXA11 axis may provide a valuable therapeutic strategy against colorectal cancer.

Indexed as

colorectal cancerglutamine metabolismHSF1LINC00857super enhancer

Identifiers

PMID36010849
PMCPMC9406190
OpenAlexW4293677740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.